SOLVE

Solve Therapeutics is a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates for solid tumors. The company is focused on improving the therapeutic index of ADCs through its proprietary CloakLink hydrophilic linker technology, engineered antibodies, and companion diagnostic approaches for patient selection. Its lead programs, SLV-154 and SLV-324, are in Phase 1 clinical development for solid tumor malignancies. Solve also describes work in bispecific therapeutics, though its disclosed pipeline is centered on ADCs. The company has raised substantial private financing to advance its clinical assets and platform capabilities in oncology.